dual-specificity Tyrosine-Regulated Kinase 1A
dual-specificity Tyrosine-Regulated Kinase 1A
Overview
Dual-specificity Tyrosine-Regulated Kinase 1A (DYRK1A) is a serine/threonine and tyrosine kinase belonging to the DYRK subfamily of the CMGC kinase group. It is encoded by the DYRK1A gene, which maps to chromosome 21q22.13 — a region implicated in Down syndrome — and is evolutionarily conserved from yeast to humans. The enzyme derives its name from its dual-specificity catalytic mechanism: during translation it autophosphorylates a critical tyrosine residue within its activation loop, yet in its mature form it predominantly phosphorylates serine and threonine residues on downstream substrates. DYRK1A is broadly expressed in the brain, kidney, heart, and other tissues, where it participates in a wide range of cellular processes including cell cycle regulation, neuronal differentiation, splicing factor control, and apoptosis. Its catalytic activity is tightly linked to the phosphorylation of microtubule associated protein tau, making it a central node in the signaling cascades that govern both neurodegeneration and tissue aging.
Pathologically, DYRK1A overactivity has been associated with accelerated cellular senescence, tau hyperphosphorylation leading to neurofibrillary tangle accumulation, and progressive fibrotic remodeling of solid organs. These pleiotropic roles have positioned DYRK1A as a high-priority therapeutic target in conditions ranging from Alzheimer's disease and related tauopathies to chronic renal insufficiency. Several small-molecule inhibitors — most prominently the natural alkaloid harmine — have been characterized as potent and selective DYRK1A inhibitors, spurring intensive drug discovery campaigns aimed at harnessing kinase inhibition for both neurological and non-neurological indications.
Focus of Latest Publications
Renal fibrosis and cellular senescence. A 2026 study published in Mechanisms of Ageing and Development (PMID 42119856) directly investigated the contribution of DYRK1A to renal interstitial fibrosis (RIF) through the lens of tubular epithelial cell (TEC) senescence. The authors demonstrated that DYRK1A accelerates cellular senescence and that its specific inhibitor harmine can mitigate this process. Mechanistically, the work identified the FOXO1–NF-κB signaling axis as the downstream effector through which DYRK1A drives pro-senescent and pro-fibrotic transcriptional programs; pharmacological or genetic abrogation of DYRK1A activity disrupted this axis and attenuated RIF in a preclinical setting. These findings are particularly relevant to chronic renal insufficiency, a condition in which progressive tubular senescence and interstitial scarring converge to drive irreversible functional decline.
Multi-target inhibition in tauopathies and Alzheimer's disease. Two studies published in 2026 illuminate DYRK1A's central role in tau pathology and the rationale for polypharmacological inhibitor design. Work appearing in ACS Chemical Neuroscience (PMID 41995061) employed machine learning and all-atom molecular dynamics simulations to characterize how dysregulation of DYRK1A — alongside Tau Tubulin Kinase 1 (TTBK1) and ABL Proto-Oncogene 1 Non-Receptor Tyrosine Kinase (ABL1) — drives excessive phosphorylation of microtubule associated protein tau and subsequent neurofibrillary tangle accumulation. The study screened for multitarget kinase inhibitors capable of simultaneously suppressing this convergent kinase network. Complementarily, a medicinal chemistry campaign reported in the Journal of Medicinal Chemistry (PMID 42054438) exploited the interconnected roles of GSK-3β, FYN, and DYRK1A in tau hyperphosphorylation to rationally design amino-pyrazole-based multikinase inhibitors. Using computational structure-activity relationship (SAR) exploration anchored by X-ray crystallography of the previously disclosed inhibitor ARN25068, the authors generated a series of optimized compounds with refined potency across all three kinase targets, demonstrating that co-inhibition of this triad represents a mechanistically coherent strategy for attenuating tau pathology in Alzheimer's disease and broader tauopathies.
Metabolic disease and obesity. A 2026 computational study in the Journal of Computer-Aided Molecular Design (PMID 42162325) extended the therapeutic relevance of DYRK1A to metabolic disease. In silico profiling of the novel candidate compound Fmol021 — designed primarily as a multi-agonist engaging incretin signaling via GLP1R — revealed secondary indications of DYRK1A modulation alongside activation of the stress-sensing protein Sestrin2. The authors proposed that this multi-target mechanism could address obesity through complementary metabolic and antioxidant pathways, positioning DYRK1A modulation as a potential adjunct to incretin-based pharmacology in the treatment of obesity.
Key Publications
- Jun Small-molecule inhibitors of the protein kinase DYRK as potential therapeutic candidates in cancer. (Cell chemical biology, 2026, PMID 42269611): "Dual-specificity tyrosine-regulated kinase 1A (DYRK1A) is crucial for normal brain development, and its disruption is linked to various cancers."
- Jun Targeting DYRK1A with harmine abrogates the FOXO1-NF-κB axis to alleviate cellular senescence and renal fibrosis. (Mechanisms of ageing and development, 2026, PMID 42119856): "Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) accelerates cellular senescence, and its specific inhibitor Harmine is hypothesized to mitigate renal interstitial fibrosis (RIF) by targeting DYRK1A to alleviate TEC senescence."
- May Identification of a novel oral potential multiple agonist for obesity treatment: multi-target in silico study. (Journal of computer-aided molecular design, 2026, PMID 42162325): "Beyond incretin signaling, Fmol021 showed in silico indications of a multi-target mechanism involving the potential activation of Sestrin2 and modulation of DYRK1A, addressing obesity through both metabolic and antioxidant pathways."
- May A Polypharmacology-Driven Approach to Alzheimer's Disease and Tauopathies: Rational Design, Synthesis and Characterization of Amino-Pyrazole-Based Multikinase (GSK-3β/FYN-α/DYRK1A) Inhibitors. (Journal of medicinal chemistry, 2026, PMID 42054438): "Leveraging the interconnected roles of GSK-3β, FYN, and DYRK1A in tau hyperphosphorylation, we conducted a computational and X-ray crystallography-driven SAR exploration around our previously disclosed GSK-3β/FYN/DYRK1A inhibitor ARN25068 (1)."
- May Machine Learning-Driven Ensemble Screening of Multitarget Kinase Inhibitors for Tauopathy-Associated Neurodegeneration Using All-Atom and Steered MD Simulations. (ACS chemical neuroscience, 2026, PMID 41995061): "Dysregulation of key kinases such as dual-specificity Tyrosine-Regulated Kinase 1A (DYRK1A), Tau Tubulin Kinase 1 (TTBK1), and ABL Proto-Oncogene 1, and Non-Receptor Tyrosine Kinase (ABL1) drives excessive tau phosphorylation and neurofibrillary tangle accumulation."